calcium dobesilate monohydrate / Generic mfg. - LARVOL DELTA

Effect of calcium dobesilate on macular microvasculature in patients with diabetic retinopathy. (PubMed, PLoS One) - "The administration of CaD positively influences macular microcirculation in DR patients, demonstrating its effectiveness even in advanced stages of the disease."

Journal • Retrospective data • Diabetic Retinopathy • Retinal Disorders

Longitudinal changes in each retinal layer thickness in patients with moderate or more severe diabetic retinopathy taking calcium dobesilate. (PubMed, PLoS One) - "In patients with moderate or more severe DR, the group taking CaD did not show significant reductions in GCC and INL thicknesses over time compared with the group not taking CaD. These findings suggest that CaD could have a protective effect on the inner retina, even in those with more advanced stages than mild DR."

Journal • Retrospective data • Diabetic Retinopathy • Retinal Disorders

Clinical evidence of venoactive drugs in diabetic microvascular complications: a scoping review. (PubMed, Int Angiol) - "Calcium dobesilate (CaD), was the most assessed VAD in DR (85%), DN (86%), and DPN (50%)...Our findings suggest that VADs, in particular CaD, may represent a promising therapeutic option for the treatment of patients with both CVD and DmVC. Medical recommendations for VADs prescription should consider patients' microvascular status, evidence about VADs, as well as the multi-modal treatment approach."

Journal • Diabetic Nephropathy • Diabetic Neuropathy • Diabetic Retinopathy • Nephrology • Pain • Renal Disease • Retinal Disorders

Acupuncture and related therapies for diabetic retinopathy: A systematic review and network meta-analysis. (PubMed, Medicine (Baltimore)) - "EA combined with AC combined with TCM may be the most effective treatment for DR. AC and the related treatments have significant efficacy in treating DR, improving vision, and reducing macular edema with relatively few adverse effects. The use of integrative therapies combining AC and its related therapies can be promoted."

Clinical • Journal • Retrospective data • Review • Diabetes • Diabetic Retinopathy • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Combining ranibizumab with calcium dobesilate to reduce injection frequency in diabetic macular edema treatment. (PubMed, Int Ophthalmol) - "Combination therapy with calcium dobesilate and ranibizumab decreased the frequency of intravitreal injections and led to greater improvements in BCVA and CMT compared to ranibizumab alone over 12 months. Both treatments were well-tolerated, with the combination therapy demonstrating a favorable safety profile."

Clinical • Journal • Diabetic Macular Edema • Ophthalmology

Efficacy and Safety of Qiming Granule for Nerve Injury Associated with Non-proliferative Diabetic Retinopathy: A Multicenter, Randomized, Non-inferiority, Active-Controlled Clinical Trial. (PubMed, Chin J Integr Med) - "Qiming Granule demonstrates non-inferiority in terms of efficacy and safety as an early treatment for nerve injury associated with NPDR. (Registration No. ISRCTN39825773)."

Clinical • Head-to-Head • Journal • Diabetic Retinopathy • Retinal Disorders

"The Role of Venoactive Compounds in the Treatment of Chronic Venous Disease". (PubMed, J Vasc Surg Venous Lymphat Disord) - "The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and non-interventional approaches like compression, to optimize patient outcomes and improve quality of life."

Journal • Review • Inflammation • Pain • Venous Ulcer

Minimizing serum creatinine interference in automated laboratory analyses through the implementation of urea/creatinine ratio alerting mechanisms. (PubMed, Clin Chim Acta) - "The implementation of an automated UCR-based screening protocol has been shown to efficiently pinpoint samples with drug-related interference. This strategic approach not only decreases clinical risk but also guarantees the fidelity of serum Cr measurements without undermining the overall productivity of the laboratory's automated workflow."

Journal

Fasting/postprandial, single oral, randomized, open, two-formulation, two-cycle, cross-over bioequivalence study of calcium dobesilate capsules in healthy subjects (ChiCTR) - P=N/A | N=52 | Completed | Sponsor: Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University; Affiliated Hospital of Traditional Chinese Medicine of Southwest

New trial • Cardiovascular

Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: University of Health Sciences Lahore

New trial • Gynecology • Women's Health

TXA: Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin (clinicaltrials.gov) - P2/3 | N=100 | Completed | Sponsor: District Headquarters Teaching Hospital Sahiwal

New P2/3 trial • Agranulocytosis • Granulocytopenia • Immunology

Discovery of a potent, Kv7.3-selective potassium channel opener from a Polynesian traditional botanical anticonvulsant. (PubMed, Commun Chem) - "GA is, uniquely to our knowledge, 100% selective for Kv7.3 versus other Kv7 homomers; it requires S5 residue Kv7.3-W265 for Kv7.2/3 activation, and it ameliorates pentylenetetrazole-induced seizures in mice. Structure-activity studies revealed that the FDA-approved vasoprotective drug calcium dobesilate, a GA analog, is a previously unrecognized Kv7.2/3 channel opener. Also an active aspirin metabolite, GA provides a molecular rationale for the use of T. populnea as an anticonvulsant in Polynesian indigenous medicine and presents novel pharmacological prospects for potent, isoform-selective, therapeutic Kv7 channel activation."

Journal • CNS Disorders • Epilepsy

Which dose of calcium dobesilate is more effective and safe in chronic venous insufficiency? Multicenter retrospective clinical trial. (PubMed, Phlebology) - "Higher doses of calcium dobesilate markedly enhance the management of CVI symptoms and reduce edema more effectively than lower doses, particularly in patients with advanced CVI. These findings support the use of higher dosages for optimal treatment, though further research is needed to fully evaluate long-term safety."

Journal • Retrospective data • Cardiovascular

Correction of negative-interference from calcium dobesilate in the Roche sarcosine oxidase creatinine assay using CuO. (PubMed, Clin Chem Lab Med) - No abstract available

Journal

Effect of HMP on Diabetic Microangiopaemia in T2DM (clinicaltrials.gov) - P4 | N=40 | Completed | Sponsor: Affiliated Hospital of Nantong University | Recruiting ➔ Completed | N=60 ➔ 40

Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • CST3 • FABP4 • TNFA • VEGFA

Effect of HMP on Diabetic Microangiopaemia in T2DM (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Affiliated Hospital of Nantong University | Trial completion date: Nov 2023 ➔ May 2024 | Trial primary completion date: Nov 2023 ➔ May 2024

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • CST3 • FABP4 • TNFA • VEGFA

Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial. (PubMed, BMJ Open) - P2 | "Dissemination of results will be through presentations at scientific conferences and publication in scientific journals. NCT05305508; Clinicaltrials.gov; Swiss National Clinical Portal Registry (SNCTP 000004938)."

Clinical • Clinical protocol • Journal • P2 data • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Assessment of the Tolerance of Dobenox Forte® in Patients with Chronic Venous Disease. (PubMed, Life (Basel)) - "This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte®, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice...The percentages of patients reporting moderate to very severe lower limb heaviness decreased from 96.6% to 56.0%, calf cramps decreased from 91.0% to 41.0%, calf pain decreased from 89.2% to 43.7%, swelling decreased from 86.1% to 38.8%, and burning sensation that worsens when standing decreased from 79.0% to 33.7%. The medicinal product Dobenox Forte® is well tolerated by patients and seems to effectively reduce the symptoms of CVD."

Clinical • Journal • Pain

CADOVID: Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19. (clinicaltrials.gov) - P2 | N=74 | Completed | Sponsor: Hervé SPECHBACH | Not yet recruiting ➔ Completed | Trial completion date: Mar 2023 ➔ Feb 2024 | Trial primary completion date: Jan 2023 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The effectiveness and safety of Chinese patent medicines plus calcium dobesilate for the treatment of diabetic retinopathy: A network meta-analysis. (PubMed, Heliyon) - "As for safety profile that CPMs plus CD did not increase the incidence of adverse events. The results of this study might support DS as a relatively prior adjuvant therapy option for patients with DR."

Journal • Retrospective data • Diabetic Retinopathy • Retinal Disorders

Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Oral Formulations of Calcium Dobesilate Capsules in Healthy Chinese Volunteers Under Fasting and Fed Conditions. (PubMed, Clin Pharmacol Drug Dev) - "Our findings revealed that the calcium dobesilate capsules used as the reference and the test drugs were both bioequivalent. Irrespective of whether the healthy Chinese volunteers consumed food or not, the PK and safety profiles were comparable."

Journal • PK/PD data • Hematological Disorders

Calcium Dobesilate Ameliorates Cisplatin-induced Hepatotoxicity by Inhibiting Liver Oxidative Stress in Mice. (PubMed, Iran J Pharm Res) - "Moreover, CD (100 mg/kg) elevated the SOD and GPx activity in the liver tissue of cisplatin-treated mice. The findings showed that CD has a protective effect against cisplatin-induced hepatotoxicity, at least by improving the antioxidant parameters."

Journal • Preclinical • Hepatology • Oncology • ICAM3

The effect of calcium dobesilate combined with hypoglycemic drugs in the treatment of cataract NPDR and its effect on fundus microcirculation and blood ICAM-1, MCP-1 and MIF levels. (PubMed, J Med Biochem) - "ICAM-1, MCP-1, MIF, vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF1) in the observation after treatment were reduced vs. the control, but pigment epithelium-derived factor (PEDF) were higher vs. the control (P 0.05). Calcium dobesilate combined with hypoglycemic drugs has good clinical efficacy in the treatment of cataract complicated with NPDR, which can effectively reduce the level of blood glucose and blood lipids, reduce inflammation, and mitigate the microcirculation of branch retinal vein occlusion lesions."

Journal • Age-related Macular Degeneration • Cataract • Diabetic Retinopathy • Dyslipidemia • Gastrointestinal Disorder • Hematological Disorders • Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • ICAM1 • IGF1 • MIF

Calcium dobesilate-induced hyperpyrexia: A case report. (PubMed, Medicine (Baltimore)) - "Moreover, misdiagnosis and mistreatment of this condition can deteriorate the patient's condition. Herein, we report a case of calcium dobesilate-induced hyperpyrexia that occurred during the treatment of chronic renal insufficiency. Subsequently, a systematic analysis of the patient's diagnosis and treatment was reviewed. If unexplained high fever develops during the use of calcium dobesilate, calcium dobesilate-induced hyperpyrexia should be considered. Accordingly, calcium dobesilate should be discontinued."

Journal • Chronic Kidney Disease • Infectious Disease • Nephrology • Renal Disease

Calcium dobesilate prevents PLD-induced hand-foot syndrome by alleviating capillary endothelial tight junction injury via the HA/CD44 pathway. (PubMed, Am J Cancer Res) - "Pegylated liposomal doxorubicin (PLD) has excellent therapeutic efficacy in the treatment of cancers, but can cause serious adverse reactions such as hand-foot syndrome (HFS). In summary, our data suggest that PLD may promote the destruction of TJs via the HA/CD44 pathway, thereby leading to HFS through increased skin permeability and exacerbated doxorubicin extravasation. Moreover, CaD can inhibit this pathway, offering a potential therapeutic avenue to alleviate HFS."

Journal • Dermatology • Oncology • CD44 • CLDN5 • TJP1